Fazoh
Ask when Sign in

Take a position on when the future happens, defend it with sources, and let time decide.

  • Take a position on the record, with a timestamped receipt
  • Argue both sides with sources, and change minds
  • Earn Debate points for your arguments and Reality points once time decides
Climate Far future Markets Politics Science Space Sports Technology

Fazoh · The mirror of the future

When will the FDA approve a gene-editing therapy that works inside the body?

Asked by replicated Team Ruled by Faz on Oct 13, 2026

Track this date Get a notice when Faz rules a new date, or it happens.

Faz's date

2027

Most likely between 2027 and 2030. Faz rules on the evidence and both sides of the debate, and gives its reasons below.

Positions No positions yet Take yours

Next ruling due Nov 12. Faz rules at most once a month, sooner only when something major happens. How it rules

Faz's date over time, from 2028 to 2027 2025 2030 2035 13 Oct 2026: 2028 13 Oct 2026: 2027 14 Oct 2026: 2027 15 Oct 2026: 2027 16 Oct 2026: 2027 17 Oct 2026: 2027 18 Oct 2026: 2027 19 Oct 2026: 2027 20 Oct 2026: 2027 21 Oct 2026: 2027 22 Oct 2026: 2027 23 Oct 2026: 2027 24 Oct 2026: 2027 25 Oct 2026: 2027 26 Oct 2026: 2027 27 Oct 2026: 2027 28 Oct 2026: 2027 29 Oct 2026: 2027 30 Oct 2026: 2027 31 Oct 2026: 2027 1 Nov 2026: 2027 2 Nov 2026: 2027 Oct 2026 Nov 2026
Faz's dateits range

Faz's reasons

Reference class: first-of-a-kind therapies that reach an FDA action date with a positive Phase 3 trial and Priority Review. The nearest precedent is Casgevy, the first CRISPR therapy, approved in December 2023, though its cells are edited outside the body. What weighed most in this ruling is HAELO, a placebo-controlled Phase 3 trial of lonvo-z that met its primary and all key secondary endpoints, and an application the FDA has accepted with a target action date of 10 March 2027. On the other side, Intellia itself calls in vivo CRISPR editing largely unproven, nex-z's liver problem has a genetic pattern but no settled cause, and this agency has turned down a rare-disease gene therapy over its trial design and a surrogate endpoint. That is why the range runs past 2027: a rejection in March would push the first approval to a resubmission or to the programmes behind it, such as Beam's BEAM-302 in a pivotal cohort aimed at accelerated approval, nex-z in Phase 3, and personalised editors under the FDA's draft plausible mechanism guidance. With several independent routes and a decision already on the calendar, the question is the year, not whether: the ruling is 2027, with a range to 2030.

What the ruling rests on

  1. For it happening

    HAELO, a placebo-controlled Phase 3 trial of lonvo-z, met its primary and all key secondary endpoints, with an 87% reduction in monthly attacks.

    “HAELO met its primary and all key secondary endpoints, demonstrating an 87% reduction (p<0.0001) in mean monthly attacks for lonvo-z compared with placebo during the efficacy evaluation period (weeks 5 to 28).”
    Intellia Therapeutics (SEC filing) · Sep 2026
  2. For it happening

    The FDA accepted the lonvo-z application with Priority Review and a target action date of 10 March 2027.

    “today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.”
    Intellia Therapeutics (SEC filing) · Sep 2026
  3. For it happening

    The FDA has already approved a CRISPR therapy, Casgevy, in December 2023, though its cells are edited outside the body.

    “Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology. Patients’ hematopoietic (blood) stem cells are modified by genome editing using CRISPR/Cas9 technology.”
    US Food and Drug Administration · Dec 2023
  4. For it happening

    Beam has begun dosing a pivotal cohort of its base editor BEAM-302, designed to support accelerated approval in the United States.

    “In July, Beam dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease. The cohort is designed to support a potential accelerated approval path in the United States.”
    Beam Therapeutics (SEC filing) · Aug 2026
  5. For it happening

    The FDA's draft plausible mechanism guidance sets out how individualised genome-editing therapies can show effectiveness and safety when only a few patients can be treated.

    “The draft guidance describes considerations for generating substantial evidence of effectiveness and evidence of safety of individualized therapies based on a plausible mechanism framework. The guidance specifically discusses genome editing and RNA-based therapies”
    US Food and Drug Administration (Federal Register) · Feb 2026
  6. Against

    Intellia's own filing describes in vivo CRISPR editing as relatively new and its therapeutic utility as largely unproven.

    “Although there have been significant advances in recent years in the fields of gene therapy and genome editing, in vivo CRISPR-based genome editing technologies are relatively new and their therapeutic utility is largely unproven.”
    Intellia Therapeutics (SEC filing) · Aug 2026
  7. Against

    The worst liver enzyme rises seen with nex-z cluster in carriers of one HLA allele, a pattern still under discussion with the FDA rather than a settled cause.

    “The analysis revealed that the highest observed liver transaminase elevations were in patients carrying one specific human leukocyte antigen (“HLA”) allele.”
    Intellia Therapeutics (SEC filing) · Aug 2026
  8. Against

    The FDA rejected a rare-disease gene therapy in February 2026 over its patient population, a natural history control and a biomarker used as a surrogate endpoint.

    “RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history control arm and the use of a biomarker as a surrogate endpoint”
    Fierce Biotech · Mar 2026

What would change the ruling

  • The FDA's action on lonvo-z by 10 March 2027: an approval settles the topic, and a complete response letter moves the year later, by more if it cites safety than if it cites manufacturing.
  • A safety finding that the FDA applies to every editor delivered to the liver by lipid nanoparticles would weaken the programmes behind lonvo-z as well.
  • Beam's pivotal BEAM-302 data, and whether the FDA accepts its biomarker endpoint for accelerated approval.
  • What Intellia and the FDA conclude about the HLA finding for the nex-z Phase 3 trials.
  • A final version of the plausible mechanism guidance, or a first application filed under it.

The two sides

Every argument takes a side and brings its evidence. Faz weighs them by their sources and reasoning, never by how many agree.

It will happen1 answer It won’t happen1 answer

Sign in to argue a side

The case that it will happen

replicated Team argued Will happen

@replicated · Rev. 1 ·

The first in vivo editor has a positive Phase 3 trial and an FDA action date of 10 March 2027, with more programmes behind it, so the first approval comes in 2027.

The design first. HAELO was a placebo-controlled Phase 3 trial (n = 80) of a single 50 mg dose of lonvo-z; it met its primary and all key secondary endpoints, with an 87% reduction in mean monthly attacks during weeks 5 to 28 [1]. In the lonvo-z arm, all treatment-emergent adverse events were mild or moderate, and no serious adverse event was observed [2]. That is what was measured.

What follows is a regulatory conclusion, and the regulator has set its own date: the application was accepted with Priority Review and a target action date of 10 March 2027 [3]. A first-cycle approval on that date is consistent with the data. It is not yet a decision, and 2027 is the year I defend.

The strongest objection, and the one @shipdate makes, is liver safety. It is a fair one. The liver toxicity that halted nex-z was observed in a different programme with a different target, and the lonvo-z trial-arm safety data contain no such signal [2]. A complete response letter would delay the date rather than remove it, because the queue behind lonvo-z is not empty: Beam has dosed the first patient in a pivotal cohort of BEAM-302 designed to support accelerated approval [4], and the FDA's draft plausible mechanism guidance sets out how evidence of effectiveness can be generated for individualised genome-editing products [5].

What would settle it is the action letter in March 2027. What would move me later is a complete response letter that cites a safety question for the whole class rather than a manufacturing one.

  1. [1] Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) · Intellia Therapeutics (SEC filing), Sep 8, 2026 HAELO met its primary and all key secondary endpoints, demonstrating an 87% reduction (p<0.0001) in mean monthly attacks for lonvo-z compared with placebo during the efficacy evaluation period (weeks 5 to 28).
  2. [2] Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) · Intellia Therapeutics (SEC filing), Sep 8, 2026 All reported treatment emergent adverse events were mild or moderate and there were no serious adverse events observed in the lonvo-z arm.
  3. [3] Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) · Intellia Therapeutics (SEC filing), Sep 8, 2026 today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.
  4. [4] Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) · Beam Therapeutics (SEC filing), Aug 4, 2026 In July, Beam dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease. The cohort is designed to support a potential accelerated approval path in the United States.
  5. [5] Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability · US Food and Drug Administration (Federal Register), Feb 25, 2026 The draft guidance describes considerations for generating substantial evidence of effectiveness and evidence of safety of individualized therapies based on a plausible mechanism framework. The guidance specifically discusses genome editing and RNA-based therapies

Open review flags Citation needed · 1

Cite

Cite this answer

replicated (2026, October 13). The first in vivo editor has a positive Phase 3 trial and an FDA action date of 10 March 2027, with more programmes behind it, so the first approval comes in 2027. [Answer to "When will the FDA approve a gene-editing therapy that works inside the body?", revision 1]. Fazoh. https://www.fazoh.com/claims/fda-approves-in-vivo-gene-editing-2100/questions/fda-approves-in-vivo-gene-editing-2100-sides#answer-163

The case that it won’t

shipdate Team argued Won’t happen

@shipdate · Rev. 1 ·

Every candidate shares one delivery route to the liver and makes an edit that cannot be undone, and one class-wide safety signal could hold the whole field back past 2100.

I'm taking the harder side here, and I know it. Lonvo-z has a real shot in March. But the question is bigger than one drug, so here's the case that this keeps not happening.

Start with what Intellia tells its own investors: in vivo CRISPR editing is relatively new and its therapeutic utility is largely unproven [1]. That's not a skeptic talking. That's the company with the lead product.

Then the liver. Nex-z sat on a clinical hold until early this year, and the best explanation so far is a pattern: the worst enzyme spikes showed up in people carrying one specific HLA allele [2]. A pattern isn't a cause. Verve hit its own liver and platelet signal and paused VERVE-101 back in 2024 [3]. Nearly every candidate in this race is a lipid nanoparticle headed for the liver.

Think of a house where every room runs off the same old wiring. One room trips the breaker and the inspector doesn't just check that room.

And the edit is permanent. The FDA recommends follow-up for up to 15 years after a genome-editing product is given [4], so a late signal lands on the whole class, not on one label. The personalized route doesn't skip this either: the CHOP and Penn team read the new guidance as asking for late-stage rigor in an early-stage trial [5].

replicated's best point is HAELO itself, clean safety and a date on the calendar. I could be wrong here becuase one approval ends this argument for good, and March is close.

What I'd watch next spring: whether the action letter says anything about the liver.

  1. [1] Intellia Therapeutics quarterly report (Form 10-Q), Q2 2026 · Intellia Therapeutics (SEC filing), Aug 6, 2026 Although there have been significant advances in recent years in the fields of gene therapy and genome editing, in vivo CRISPR-based genome editing technologies are relatively new and their therapeutic utility is largely unproven.
  2. [2] Intellia Therapeutics quarterly report (Form 10-Q), Q2 2026 · Intellia Therapeutics (SEC filing), Aug 6, 2026 The analysis revealed that the highest observed liver transaminase elevations were in patients carrying one specific human leukocyte antigen (“HLA”) allele.
  3. [3] Verve Therapeutics current report (Form 8-K), 2 April 2024 · Verve Therapeutics (SEC filing), Apr 2, 2024 In light of such observed laboratory abnormalities associated with VERVE-101, Verve, in consultation with the study’s independent data and safety monitoring board, has decided to pause enrollment in the Heart-1 trial.
  4. [4] Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry · US Food and Drug Administration, Jan 30, 2024 Therefore, we recommend that sponsors conduct LTFU for up to 15 years after product administration
  5. [5] Implications of the FDA’s new plausible mechanism framework for the development of a personalized in vivo prime editing platform · The American Journal of Human Genetics (via PMC), Mar 31, 2026 an abbreviated pathway to an FDA approval—entailing only a single clinical trial—appears to be dependent on a sponsor’s ability to apply the strict requirements ordinarily reserved for late-stage clinical trials to an early-stage clinical trial.
Cite

Cite this answer

shipdate (2026, October 13). Every candidate shares one delivery route to the liver and makes an edit that cannot be undone, and one class-wide safety signal could hold the whole field back past 2100. [Answer to "When will the FDA approve a gene-editing therapy that works inside the body?", revision 1]. Fazoh. https://www.fazoh.com/claims/fda-approves-in-vivo-gene-editing-2100/questions/fda-approves-in-vivo-gene-editing-2100-sides#answer-164

Quick poll

With the first in vivo editor now under FDA review, which factor do you think matters most for whether it is approved on the first cycle?

Liver safety with lipid nanoparticle delivery Long-term follow-up of a permanent edit Manufacturing and quality review of the application The FDA's review calendar and staffing Durability of the effect beyond the trial window

You see how people answered once you have.

Your position

Sign in to take a position: it will happen, and in which year, or it won’t. You get a timestamped receipt that nobody can rewrite, including you.

Sign in to take a position

What this is about

The FDA has approved one CRISPR therapy, Casgevy, in December 2023, but its cells are edited outside the body and then returned to the patient. No therapy that edits genes inside the body has yet been approved in the United States. The first candidate is Intellia's lonvo-z for hereditary angioedema: its placebo-controlled Phase 3 trial, HAELO, met its primary and all key secondary endpoints, and the FDA has accepted the application under Priority Review with a target action date of 10 March 2027. Behind it are Intellia's nex-z for transthyretin amyloidosis, in two Phase 3 trials since a clinical hold over liver toxicity was lifted in early 2026; Beam's base editor BEAM-302 for alpha-1 antitrypsin deficiency, in a pivotal cohort designed to support accelerated approval; Lilly's base editor VERVE-102 for high cholesterol, due to enter Phase 2; and personalised editors for ultra-rare diseases under the FDA's draft plausible mechanism guidance. What decides it: the March 2027 action, liver safety across editors delivered by lipid nanoparticles, and how the agency weighs an edit that cannot be undone.

What counts: Happens on the date the US Food and Drug Administration grants full (traditional) or accelerated approval to a therapy that edits genes inside the patient's body (in vivo) using CRISPR-Cas or a CRISPR-derived base or prime editor, for any disease and from any sponsor. The therapy must change the DNA sequence of the patient's cells where they are, after it is given to the patient. The date that counts is the date of the approval letter; the first such approval settles it, and a later withdrawal does not undo it. Does not count: therapies whose cells are edited outside the body and then given back (ex vivo), such as Casgevy; expanded access, single-patient use or any other use without approval; approvals by regulators other than the FDA; editors not derived from CRISPR, such as zinc-finger nucleases, TALENs or meganucleases; therapies that silence or regulate a gene without changing its DNA sequence, such as siRNA, antisense drugs or epigenetic editors. Source: the FDA's approval letter or press announcement, or its list of approved cellular and gene therapy products.

Share, embed or cite

The date updates itself wherever it is shown: put it in an article, a slide or a paper.

When will the FDA approve a gene-editing therapy that works inside the body? · Faz's date

Embed (HTML) 
<a href="https://www.fazoh.com/when/fda-approves-in-vivo-gene-editing"><img src="https://www.fazoh.com/when/fda-approves-in-vivo-gene-editing/badge.svg" alt="When will the FDA approve a gene-editing therapy that works inside the body? · Faz's date on Fazoh" width="440" height="96"></a>
Cite (APA)

Fazoh. (2026). When will the FDA approve a gene-editing therapy that works inside the body? Faz's date: 2027 (2027–2030). Retrieved 3 November 2026, from https://www.fazoh.com/when/fda-approves-in-vivo-gene-editing

Cite (BibTeX) 
@misc{fazoh_fda_approves_in_vivo_gene_editing,
  title = {When will the FDA approve a gene-editing therapy that works inside the body?},
  author = <?php echo e(Fazoh); ?>,
  year = {2026},
  note = {Faz's date: 2027, most likely 2027–2030},
  howpublished = {\url{https://www.fazoh.com/when/fda-approves-in-vivo-gene-editing}}
}
Science When will a pig kidney keep a patient off dialysis for a full year? 2027 Faz's date · most likely 2026–2031 Science When will the world go a full calendar year with no wild poliovirus cases? 2031 Faz's date · most likely 2028–2046 Space When will people live on the Moon for a full year without a break? 2050 Faz's date · most likely 2040–2078 Technology When will driverless taxis carry paying riders in 25 US metro areas? 2028 Faz's date · most likely 2027–2031

Sources in the debate

  1. Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) Intellia Therapeutics (SEC filing) · 2026
  2. Intellia Therapeutics quarterly report (Form 10-Q), Q2 2026 Intellia Therapeutics (SEC filing) · 2026
  3. Verve Therapeutics current report (Form 8-K), 2 April 2024 Verve Therapeutics (SEC filing) · 2024
  4. Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry US Food and Drug Administration · 2024
  5. Implications of the FDA’s new plausible mechanism framework for the development of a personalized in vivo prime editing platform The American Journal of Human Genetics (via PMC) · 2026
  6. Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Beam Therapeutics (SEC filing) · 2026
  7. Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability US Food and Drug Administration (Federal Register) · 2026

How Faz rules

Faz is a referee, not a forecaster. People take positions and defend them with evidence; Faz weighs the sources and arguments on both sides, the questions on the road to it, official data and what has changed in the world, here and on the wider web, and rules a date with a range. While the evidence is too weak it gives no date: the question is watching, and stays open for debate. It rules at most once a month, sooner only when something major happens, gives its reasons every time, and every ruling stays on the record. How it weighs each piece is its own. When it happens, the question goes into the archive, where Faz's dates are set against the real one. More on How Faz works.